Why the study?
The Wnt/β-catenin pathway is proposed to be involved in arterial stiffness, but the relationship between the pathway inhibitor sclerostin and carotid-femoral pulse wave velocity in hypertensive patients remained to be investigated.
Are serum sclerostin levels associated with central arterial stiffness in hypertensive patients?
Are serum sclerostin levels associated with central arterial stiffness in hypertensive patients?
Serum sclerostin levels are independently associated with central arterial stiffness in hypertensive patients, suggesting its potential utility as a biomarker for vascular aging.
Serum sclerostin associates with arterial stiffness in hypertension; leaves open its value as biomarker or target pending prospective studies.
Sclerostin is known to be a canonical Wnt/β-catenin signaling pathway inhibitor, while the Wnt/β-catenin signaling pathway is proposed to be involved in the development of arterial stiffness. This study aims to investigate the relationship between serum sclerostin levels and carotid–femoral pulse wave velocity (cfPWV) among hypertensive patients. Fasting blood samples were obtained from 105 hypertensive patients. Patients with cfPWV values of > 10 m/s were classified in the high arterial stiffness group, whereas those with cfPWV values of ≤10 m/s were assigned to the low arterial stiffness group. Serum sclerostin and Dickkopf-1 (DKK1) levels were quantified using commercially available enzyme-linked immunosorbent assays. Thirty-six hypertensive patients (34.3%) who belonged to the high arterial stiffness group were generally older ( p < 0.001), presented with lower estimated glomerular filtration rates (eGFR, p = 0.014), higher incidence of diabetes mellitus ( p = 0.030), average systolic blood pressures (SBP, p = 0.013), pulse pressure ( p = 0.026), serum creatinine levels ( p = 0.013), intact parathyroid hormone levels (iPTH, p = 0.003), and sclerostin levels ( p < 0.001) than their counterparts in the low arterial stiffness group. A multivariable logistic regression analysis identified sclerostin as an independent predictor of arterial stiffness in hypertensive patients (odds ratio, 1.042; 95% confidence interval (CI), 1.017–1.068; p = 0.001). Multivariable forward stepwise linear regression analysis also showed that serum sclerostin level (β = 0.255, adjusted R 2 change: 0.146, p = 0.003) was positively associated with cfPWV values in patients with hypertension. In this study, serum sclerostin level, but not DKK1, is found to be positively correlated with cfPWV values and is identified as an independent predictor of arterial stiffness in hypertensive patients after adjusting for significant confounders.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: